c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations

Celina M. D'Cruz, Edward J. Gunther, Robert B. Boxer, Jennifer L. Hartman, Louis Sintasath, Susan E. Moody, James D. Cox, Seung I. Ha, George K. Belka, Alexander Golant, Robert Cardiff, Lewis A. Chodosh

Research output: Contribution to journalArticle

309 Citations (Scopus)

Abstract

Although the process of mammary tumorigenesis requires multiple genetic events, it is unclear to what extent carcinogenesis proceeds through preferred secondary pathways following a specific initiating oncogenic event. Similarly, the extent to which established mammary tumors remain dependent on individual mutations for maintenance of the transformed state is unknown. Here we use the tetracycline regulatory system to conditionally express the human c-MYC oncogene in the mammary epithelium of transgenic mice. MYC encodes a transcription factor implicated in multiple human cancers. In particular, amplification and overexpression of c-MYC in human breast cancers is associated with poor prognosis, although the genetic mechanisms by which c-MYC promotes tumor progression are poorly understood1,2. We show that deregulated c-MYC expression in this inducible system results in the formation of invasive mammary adenocarcinomas, many of which fully regress following c-MYC deinduction. Approximately half of these tumors harbor spontaneous activating point mutations in the ras family of proto-oncogenes with a strong preference for Kras2 compared with Hras1. Nearly all tumors lacking activating ras mutations fully regressed following c-MYC deinduction, whereas tumors bearing ras mutations did not, suggesting that secondary mutations in ras contribute to tumor progression. These findings demonstrate that c-MYC-induced mammary tumorigenesis proceeds through a preferred secondary oncogenic pathway involving Kras2.

Original languageEnglish (US)
Pages (from-to)235-239
Number of pages5
JournalNature Medicine
Volume7
Issue number2
DOIs
StatePublished - Feb 22 2001

Fingerprint

Tumors
Carcinogenesis
Breast
Mutation
Neoplasms
Bearings (structural)
Breast Neoplasms
Proto-Oncogenes
Ports and harbors
Tetracycline
Oncogenes
Point Mutation
Transgenic Mice
Amplification
Adenocarcinoma
Transcription Factors
Epithelium
Maintenance

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

D'Cruz, C. M., Gunther, E. J., Boxer, R. B., Hartman, J. L., Sintasath, L., Moody, S. E., ... Chodosh, L. A. (2001). c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nature Medicine, 7(2), 235-239. https://doi.org/10.1038/84691

c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. / D'Cruz, Celina M.; Gunther, Edward J.; Boxer, Robert B.; Hartman, Jennifer L.; Sintasath, Louis; Moody, Susan E.; Cox, James D.; Ha, Seung I.; Belka, George K.; Golant, Alexander; Cardiff, Robert; Chodosh, Lewis A.

In: Nature Medicine, Vol. 7, No. 2, 22.02.2001, p. 235-239.

Research output: Contribution to journalArticle

D'Cruz, CM, Gunther, EJ, Boxer, RB, Hartman, JL, Sintasath, L, Moody, SE, Cox, JD, Ha, SI, Belka, GK, Golant, A, Cardiff, R & Chodosh, LA 2001, 'c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations', Nature Medicine, vol. 7, no. 2, pp. 235-239. https://doi.org/10.1038/84691
D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nature Medicine. 2001 Feb 22;7(2):235-239. https://doi.org/10.1038/84691
D'Cruz, Celina M. ; Gunther, Edward J. ; Boxer, Robert B. ; Hartman, Jennifer L. ; Sintasath, Louis ; Moody, Susan E. ; Cox, James D. ; Ha, Seung I. ; Belka, George K. ; Golant, Alexander ; Cardiff, Robert ; Chodosh, Lewis A. / c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. In: Nature Medicine. 2001 ; Vol. 7, No. 2. pp. 235-239.
@article{b8acc8fbb3d2489fb8bf8cc19d77b288,
title = "c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations",
abstract = "Although the process of mammary tumorigenesis requires multiple genetic events, it is unclear to what extent carcinogenesis proceeds through preferred secondary pathways following a specific initiating oncogenic event. Similarly, the extent to which established mammary tumors remain dependent on individual mutations for maintenance of the transformed state is unknown. Here we use the tetracycline regulatory system to conditionally express the human c-MYC oncogene in the mammary epithelium of transgenic mice. MYC encodes a transcription factor implicated in multiple human cancers. In particular, amplification and overexpression of c-MYC in human breast cancers is associated with poor prognosis, although the genetic mechanisms by which c-MYC promotes tumor progression are poorly understood1,2. We show that deregulated c-MYC expression in this inducible system results in the formation of invasive mammary adenocarcinomas, many of which fully regress following c-MYC deinduction. Approximately half of these tumors harbor spontaneous activating point mutations in the ras family of proto-oncogenes with a strong preference for Kras2 compared with Hras1. Nearly all tumors lacking activating ras mutations fully regressed following c-MYC deinduction, whereas tumors bearing ras mutations did not, suggesting that secondary mutations in ras contribute to tumor progression. These findings demonstrate that c-MYC-induced mammary tumorigenesis proceeds through a preferred secondary oncogenic pathway involving Kras2.",
author = "D'Cruz, {Celina M.} and Gunther, {Edward J.} and Boxer, {Robert B.} and Hartman, {Jennifer L.} and Louis Sintasath and Moody, {Susan E.} and Cox, {James D.} and Ha, {Seung I.} and Belka, {George K.} and Alexander Golant and Robert Cardiff and Chodosh, {Lewis A.}",
year = "2001",
month = "2",
day = "22",
doi = "10.1038/84691",
language = "English (US)",
volume = "7",
pages = "235--239",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations

AU - D'Cruz, Celina M.

AU - Gunther, Edward J.

AU - Boxer, Robert B.

AU - Hartman, Jennifer L.

AU - Sintasath, Louis

AU - Moody, Susan E.

AU - Cox, James D.

AU - Ha, Seung I.

AU - Belka, George K.

AU - Golant, Alexander

AU - Cardiff, Robert

AU - Chodosh, Lewis A.

PY - 2001/2/22

Y1 - 2001/2/22

N2 - Although the process of mammary tumorigenesis requires multiple genetic events, it is unclear to what extent carcinogenesis proceeds through preferred secondary pathways following a specific initiating oncogenic event. Similarly, the extent to which established mammary tumors remain dependent on individual mutations for maintenance of the transformed state is unknown. Here we use the tetracycline regulatory system to conditionally express the human c-MYC oncogene in the mammary epithelium of transgenic mice. MYC encodes a transcription factor implicated in multiple human cancers. In particular, amplification and overexpression of c-MYC in human breast cancers is associated with poor prognosis, although the genetic mechanisms by which c-MYC promotes tumor progression are poorly understood1,2. We show that deregulated c-MYC expression in this inducible system results in the formation of invasive mammary adenocarcinomas, many of which fully regress following c-MYC deinduction. Approximately half of these tumors harbor spontaneous activating point mutations in the ras family of proto-oncogenes with a strong preference for Kras2 compared with Hras1. Nearly all tumors lacking activating ras mutations fully regressed following c-MYC deinduction, whereas tumors bearing ras mutations did not, suggesting that secondary mutations in ras contribute to tumor progression. These findings demonstrate that c-MYC-induced mammary tumorigenesis proceeds through a preferred secondary oncogenic pathway involving Kras2.

AB - Although the process of mammary tumorigenesis requires multiple genetic events, it is unclear to what extent carcinogenesis proceeds through preferred secondary pathways following a specific initiating oncogenic event. Similarly, the extent to which established mammary tumors remain dependent on individual mutations for maintenance of the transformed state is unknown. Here we use the tetracycline regulatory system to conditionally express the human c-MYC oncogene in the mammary epithelium of transgenic mice. MYC encodes a transcription factor implicated in multiple human cancers. In particular, amplification and overexpression of c-MYC in human breast cancers is associated with poor prognosis, although the genetic mechanisms by which c-MYC promotes tumor progression are poorly understood1,2. We show that deregulated c-MYC expression in this inducible system results in the formation of invasive mammary adenocarcinomas, many of which fully regress following c-MYC deinduction. Approximately half of these tumors harbor spontaneous activating point mutations in the ras family of proto-oncogenes with a strong preference for Kras2 compared with Hras1. Nearly all tumors lacking activating ras mutations fully regressed following c-MYC deinduction, whereas tumors bearing ras mutations did not, suggesting that secondary mutations in ras contribute to tumor progression. These findings demonstrate that c-MYC-induced mammary tumorigenesis proceeds through a preferred secondary oncogenic pathway involving Kras2.

UR - http://www.scopus.com/inward/record.url?scp=0035126052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035126052&partnerID=8YFLogxK

U2 - 10.1038/84691

DO - 10.1038/84691

M3 - Article

C2 - 11175856

AN - SCOPUS:0035126052

VL - 7

SP - 235

EP - 239

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 2

ER -